SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of IbrexafungerpGlobeNewsWire • 07/22/20
SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast InfectionsGlobeNewsWire • 07/09/20
SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and SalesGlobeNewsWire • 06/02/20
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company UpdateGlobeNewsWire • 05/11/20
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of IbrexafungerpGlobeNewsWire • 05/06/20
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)GlobeNewsWire • 04/21/20
SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase AgreementGlobeNewsWire • 04/13/20
SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance CapitalGlobeNewsWire • 04/09/20
Analysts Estimate Scynexis (SCYX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 11/05/19
Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/01/19
Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 05/07/19